Diagnostic Kits/Disease Gene Patents: Difference between revisions
Jump to navigation
Jump to search
AClearwater (talk | contribs) (New page: *Merz, J.F., 1999 - The development of the genetic testing services market is investigated by Merz using three main factors. Merz claims market structure is primarily influenced by "the n...) |
AClearwater (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
Merz, J.F., 1999. Disease Gene Patents: Overcoming Unethical Constraints on Clinical Laboratory Medicine. Clin Chem, 45(3), 324-330.(Merz 1999) Available at: http://www.clinchem.org/cgi/content/abstract/45/3/324 [Accessed August 5, 2009]. | |||
*Merz, J.F., 1999 - The development of the genetic testing services market is investigated by Merz using three main factors. Merz claims market structure is primarily influenced by "the number of patents related to a test", "the simplicity of a test may favor pure competition", and "prevalence of a disease or condition." Merz is most concerned with the effect of patents on the market structure. Merz finds the solution to monopoly issues surrounding genetic testing services to be compulsory licensing. Merz concludes that "[c]ompulsory licensing is a reasonable compromise aimed at permitting laboratory medicine to proceed subject to payment of royalties, something all laboratories already do for use of methods such as PCR." | *Merz, J.F., 1999 - The development of the genetic testing services market is investigated by Merz using three main factors. Merz claims market structure is primarily influenced by "the number of patents related to a test", "the simplicity of a test may favor pure competition", and "prevalence of a disease or condition." Merz is most concerned with the effect of patents on the market structure. Merz finds the solution to monopoly issues surrounding genetic testing services to be compulsory licensing. Merz concludes that "[c]ompulsory licensing is a reasonable compromise aimed at permitting laboratory medicine to proceed subject to payment of royalties, something all laboratories already do for use of methods such as PCR." | ||
==Navigation== | |||
[[Category:Diagnostic_Kits]] | |||
[[Main Page]] | |||
[[Diagnostic_Kits]] | |||
Latest revision as of 16:32, 10 September 2009
Merz, J.F., 1999. Disease Gene Patents: Overcoming Unethical Constraints on Clinical Laboratory Medicine. Clin Chem, 45(3), 324-330.(Merz 1999) Available at: http://www.clinchem.org/cgi/content/abstract/45/3/324 [Accessed August 5, 2009].
- Merz, J.F., 1999 - The development of the genetic testing services market is investigated by Merz using three main factors. Merz claims market structure is primarily influenced by "the number of patents related to a test", "the simplicity of a test may favor pure competition", and "prevalence of a disease or condition." Merz is most concerned with the effect of patents on the market structure. Merz finds the solution to monopoly issues surrounding genetic testing services to be compulsory licensing. Merz concludes that "[c]ompulsory licensing is a reasonable compromise aimed at permitting laboratory medicine to proceed subject to payment of royalties, something all laboratories already do for use of methods such as PCR."